On 27th April, SynerK, an innovative biopharmaceutical company focusing on developing RNA-targeted therapeutics, announced that its Phase I clinical trial of the first small interfering RNA (siRNA) product under research has been completed with the first subject enrolled for dosing. Public data shows that this is the first domestic siRNA candidate drug against a specific target, which is involved in the clinical administration and treatment phase in subjects. SynerK owns the completely independent intellectual property right.
Small interfering RNA (siRNA) drugs, as a hotspot in the development of small nucleic acid-based drugs, have been widely used for their high gene silencing efficiency, controllable adverse effects, and easy synthesis. Recently, HJB has also embraced the first siRNA formulation filling project, which was commissioned by SynerK, a leading company in siRNA technology, for the development of siRNA formulation prescriptions and filling work. During the project, the two parties cooperated and gave full play to SynerK's experience in the development and production of siRNA formulations and to HJB's experience in the development and filling of injectable liquid formulations. The technical team of HJB overcame many technical difficulties and challenges of siRNA formulation and completed the first batch of filling in one go, with a filling yield as high as 95%.
HJB congratulates its partner BioneCure for receiving IND approval for BIO-106.
HJB congratulates its client on an approval of CMC process change supplemental application filed to NMPA in support of a late phase clinical trial in China.
HJB Congratulates its partner Kanova Biopharma for receiving IND approval from U.S.FDA for XKH001, a humanized monoclonal antibody for the treatment of autoimmune disease.
HJB congratulates its partner for receiving IND approval from NMPA.
HJB Congratulates its partner Miracogen for receiving IND acceptance from NMPA for MRG004A, an tissue factor-targeted antibody–drug conjugate.